Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy

Frontiers in Immunology

Immunology

Francesco Giuseppe De Rosa¹  Ivan Hung²  Francesco Blasi³  Juan Pablo Torres⁴  Natasha B. Halasa⁵  Antonio Vena⁶  Matteo Bassetti⁶  Tina Tan⁷  Gayatri Amirthalingam⁸  Susanna Esposito⁹  Albert Osterhaus^1,10  Nicola Principi^1,11 

[1] Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy;Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China;Department of Infectious Disease and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China;Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy;Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy;Department of Pediatrics and Pediatric Surgery, Facultad de Medicina, University of Chile, Santiago, Chile;Instituto Sistemas Complejos de Ingeniería (ISCI), Santiago, Chile;Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States;Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genoa, Italy;IRCCS Ospedale Policlinico San Martino, Genoa, Italy;Division of Infectious Diseases, Feinberg School of Medicine of Northwestern University, Chicago, IL, United States;Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom;Pediatric Clinic, Pietro Barilla Children’s Hospital, Department of Medicine and Surgery, University of Parma, Parma, Italy;Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Foundation, Hannover, Germany;Università degli Studi di Milano, Milan, Italy;

关键词: bacterial infection;    COVID-19;    HIV;    infectious diseases;    monoclonal antibodies;    rabies;    RSV;   

DOI  :  10.3389/fimmu.2023.1162342

 received in 2023-02-09, accepted in 2023-04-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

Monoclonal antibodies (mABs) are safe and effective proteins produced in laboratory that may be used to target a single epitope of a highly conserved protein of a virus or a bacterial pathogen. For this purpose, the epitope is selected among those that play the major role as targets for prevention of infection or tissue damage. In this paper, characteristics of the most important mABs that have been licensed and used or are in advanced stages of development for use in prophylaxis and therapy of infectious diseases are discussed. We showed that a great number of mABs effective against virus or bacterial infections have been developed, although only in a small number of cases these are licensed for use in clinical practice and have reached the market. Although some examples of therapeutic efficacy have been shown, not unlike more traditional antiviral or antibacterial treatments, their efficacy is significantly greater in prophylaxis or early post-exposure treatment. Although in many cases the use of vaccines is more effective and cost-effective than that of mABs, for many infectious diseases no vaccines have yet been developed and licensed. Furthermore, in emergency situations, like in epidemics or pandemics, the availability of mABs can be an attractive adjunct to our armament to reduce the impact. Finally, the availability of mABs against bacteria can be an important alternative, when multidrug-resistant strains are involved.

【 授权许可】

Unknown   
Copyright © 2023 Esposito, Amirthalingam, Bassetti, Blasi, De Rosa, Halasa, Hung, Osterhaus, Tan, Torres, Vena and Principi